Signal2026-07-20
ClinicalTrials.gov

[PHASE1] BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

Part of

Early Phase Immune Therapeutics Trials

Open primary sourceRead on Substack